awmsg logo



dabrafenib (Tafinlar®)


Reference No. 2509

Publication date:
13/07/2017


Appraisal information

dabrafenib (Tafinlar®) capsule


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 12/07/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

n the absence of a submission from the holder of the marketing authorisation, dabrafenib (Tafinlar®) cannot be endorsed for use within NHS Wales in combination with trametinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
Statement of Advice (SOA)
Download